Literature DB >> 22552386

Ideal body weight-based remifentanil infusion is potentially insufficient for anesthetic induction in mildly obese patients.

Takayuki Kunisawa1, Sayuri Mitamura, Satoshi Hanada, Akihiro Suzuki, Osamu Takahata, Hiroshi Iwasaki.   

Abstract

We evaluated whether the effect of remifentanil treatment differs between normal weight (NW) patients with real body weight-based remifentanil and mildly obese (Ob) patients with ideal body weight based-remifentanil during short-term anesthetic induction. We enrolled 20 patients aged between 20 and 64 years in each group (NW group: 18.5 kg/m(2) ≤ BMI < 25 kg/m(2); Ob group: BMI ≥ 25 kg/m(2)). Tracheal intubation (TI) was performed after administration of 0.5 μg/kg/min remifentanil for 5 min, including 2 min of antecedent administration, with propofol and rocuronium. Hemodynamic parameters (SBP, DBP, and HR) were measured. Percent changes in hemodynamics resulting from anesthetic induction and TI were calculated, and effect-site concentration (ESC) in each patient was calculated by performing pharmacokinetic simulation. All hemodynamic values in the Ob group after TI were significantly higher than those in the NW group. Percent increases in SBP and HR in the Ob group were significantly higher than the corresponding values in the NW group. ESC of remifentanil at the time of TI in the NW group was higher than that in the Ob group. Remifentanil treatment with anesthetic induction based on the Japanese package insert might have insufficient effects in obese patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552386     DOI: 10.1007/s00540-012-1395-5

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  4 in total

1.  Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application.

Authors:  C F Minto; T W Schnider; S L Shafer
Journal:  Anesthesiology       Date:  1997-01       Impact factor: 7.892

2.  Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development.

Authors:  C F Minto; T W Schnider; T D Egan; E Youngs; H J Lemmens; P L Gambus; V Billard; J F Hoke; K H Moore; D J Hermann; K T Muir; J W Mandema; S L Shafer
Journal:  Anesthesiology       Date:  1997-01       Impact factor: 7.892

3.  Effects of remifentanil on propofol requirements for loss of consciousness in target-controlled infusion.

Authors:  Y S Jee; J Y Hong
Journal:  Minerva Anestesiol       Date:  2008 Jan-Feb       Impact factor: 3.051

4.  Remifentanil pharmacokinetics in obese versus lean patients.

Authors:  T D Egan; B Huizinga; S K Gupta; R L Jaarsma; R J Sperry; J B Yee; K T Muir
Journal:  Anesthesiology       Date:  1998-09       Impact factor: 7.892

  4 in total
  2 in total

1.  Comparison of the effect of continuous intravenous infusion and two bolus injections of remifentanil on haemodynamic responses during anaesthesia induction: a prospective randomised single-centre study.

Authors:  Toyoaki Maruta; Yoshihumi Kodama; Ishie Tanaka; Tetsuro Shirasaka; Isao Tsuneyoshi
Journal:  BMC Anesthesiol       Date:  2016-11-14       Impact factor: 2.217

2.  Using Lean tools to improve the efficiency of awake fibreoptic intubation setup.

Authors:  Wade A Weigel; Andrew B Lyons; Justin S Liberman; C Craig Blackmore
Journal:  BMJ Open Qual       Date:  2021-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.